INS and metabolic dysfunction-associated steatotic liver disease: Thus, although no medical treatment has been currently authorized for the management of NAFLD in patients with T2D, a growing body of evidence points to the beneficial effects of insulin-sensitivity drugs, such as pioglitazone, metformin, GLP-1RAs, and SGLT2i, irrespective of their beneficial effect on body weight [52,53,54].